Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4′-[(trifluoromethyl)pyrazol-1-yl]carboxanilides

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 21, 2008, Pages 9457-9466

  Yonetoku, Yasuhiro ^a   Kubota, Hirokazu ^a   Miyazaki, Yoji ^a   Okamoto, Yoshinori ^a   Funatsu, Masashi ^a   Yoshimura Ishikawa, Noriko ^a   Ishikawa, Jun ^a   Yoshino, Taiji ^a   Takeuchi, Makoto ^a   Ohta, Mitsuaki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Anti inflammatory; Ca2+ release activated Ca2+ channel; Channel inhibitors; CRAC channel; Interleukin 2

Indexed keywords

1 [2 (4 METHOXYPHENYL) 2 [3 (4 METHOXYPHENYL)PROPOXY]ETHYL] 1H IMIDAZOLE; 4 METHYL 4' [3,5 BIS(TRIFLUOROMETHYL) 1H PYRAZOL 1 YL] 1,2,3 THIADIAZOLE 5 CARBOXANILIDE; 4' [(TRIFLUOROMETHYL)PYRAZOL 1 YL]CARBOXANILIDE; 5 AMINO 1 [3,5 DICHLORO 4 (4 CHLOROBENZOYL)BENZYL] 1H 1,2,3 TRIAZOLE 4 CARBOXAMIDE; ANILIDE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; OVALBUMIN; THAPSIGARGIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; EOSINOPHILIA; FEMALE; HUMAN; HUMAN CELL; IC 50; NONHUMAN; RAT; T LYMPHOCYTE ACTIVATION;

ANILIDES; ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; CALCIUM SIGNALING; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERSENSITIVITY; INTERLEUKIN-2; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MALE; MICE; PULMONARY EOSINOPHILIA; PYRAZOLES; RATS; RATS, INBRED BN; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; THAPSIGARGIN;

RATTUS;

EID: 53749094649     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.09.047     Document Type: Article

References (36)

1. Mori Y., Mikala G., Varadi G., Kobayashi T., Koch S., Wakamori M., and Schwartz A. Jpn. J. Pharmacol. 72 (1996) 83
2. Hoth M., and Penner R. Nature 355 (1992) 353
3. Lewis R.S., and Cahalan M.D. Annu. Rev. Immunol. 13 (1995) 623
4. Clementi E., and Meldolesi J. Cell Calcium 19 (1996) 269
5. Geiszt M., Kapus A., Nemet K., Farkas L., and Ligeti E. J. Biol. Chem. 272 (1997) 26471
6. Clapham D.E. Cell 80 (1995) 259
7. Petersen O.H., Gerasimenko O.V., Gerasimenko J.V., Mogami H., and Tepikin A.V. Cell Calcium 23 (1998) 87
8. Berridge M.J., and Irvine R.F. Nature 341 (1989) 197
9. Putney Jr. J.W. Cell Calcium 11 (1990) 611
10. Randriamampita C., and Tsien R.Y. Nature 364 (1993) 809
11. Fasolato C., Innocenti B., and Pozzan T. Trends Pharmacol. Sci. 15 (1994) 77
12. Berridge J.M. Biochem. J. 312 (1995) 1
13. Hoth M. Pflügers Arch. 430 (1995) 315
14. Fanger C.M., Hoth M., Crabtree G.R., and Lewis R.S. J. Cell Biol. 131 (1995) 655
15. Zweifach A., and Lewis R.S. J. Biol. Chem. 270 (1995) 14445
16. Zweifach A., and Lewis R.S. J. Gen. Physiol. 107 (1996) 597
17. Slaughter R.S., Garcia M.L., and Kaczorowski G.J. Curr. Pharm. Des. 2 (1996) 610
18. Cahalan M.D., and Chandy K.G. Curr. Opin. Biotechnol. 8 (1997) 749
19. Chung S.C., McDonald T.V., and Gardner P. Br. J. Pharmacol. 113 (1994) 861
20. Christian E.P., Spence K.T., Togo J.A., Dargis P.G., and Warawa E. Br. J. Pharmacol. 119 (1996) 647
21. Felder C.C., Ma A.L., Liotta L.A., and Kohn E.C. J. Pharm. Exp. Ther. 257 (1991) 967
22. Part 1. Yonetoku Y., Kubota H., Okamoto Y., Toyoshima A., Funatsu M., Nakahara H., Yamagiwa Y., Ishikawa J., Takeuchi M., Ohta M., and Tsukamoto S. Bioorg. Med. Chem. 14 (2006) 4750
23. Part 2. Yonetoku Y., Kubota H., Okamoto Y., Ishikawa J., Takeuchi M., Ohta M., and Tsukamoto S. Bioorg. Med. Chem. 14 (2006) 5370
24. Kubota, H., Yonetoku, Y., Sugasawa, K., Funatsu, M., Kawazoe, S., Toyoshima, A., Okamoto, Y., Ishikawa, J., Takeuchi, M., WO 9919303; Chem. Abstr. 1999, 130, 311815.
25. Yoshino T., Ishikawa J., Ohga K., Morokata T., Takezawa R., Morio H., Okada Y., Honda K., and Yamada T. Eur. J. Pharmacol. 560 (2007) 225
26. Although similar carboxanilide derivatives including compound 6 were recently reported to inhibit transcriptional activity against nuclear factor of activated T cells, the observation to inhibit CRAC channel has not been described. Djuric S.W., BaMaung N.Y., Basha A., Liu H., Luly J.R., Madar D.J., Sciotti R.J., Tu N.P., Wagenaar F.L., Wiedeman P.E., Zhou X., Ballaron S., Bauch J., Chen Y.-W., Chiou X.G., Fey T., Gauvin D., Gubbins E., Hsieh G.C., Marsh K.C., Mollison K.W., Pong M., Shaughnessy T.K., Sheets M.P., Smith M., Trevillyan J.M., Warrior U., Wegner C.D., and Carter G.W. J. Med. Chem. 43 (2000) 2975
27. Sloop J.C., Bumgardner C.L., and Loehle W.D. J. Fluorine Chem. 118 (2002) 135
28. Ohmoto K., Yamamoto T., Okuma M., Horiuchi T., Imanishi H., Odagaki Y., Kawabata K., Sekioka T., Hirota Y., Matsuoka S., Nakai H., and Toda M. J. Med. Chem. 44 (2001) 1268
29. Leger R., Watkins W. J., Zhang J. Z., Renau T. E., Lee V. J., Ohta T., Nakayama K., Ishida Y., Ohtsuka M., Kawato H., WO 0130757, Chem. Abstr. 2001, 134, 336205.
30. 6.
31. Timmerman L.A., Clipstone N.A., Ho S.N., Northrop J.P., and Crabtree G.R. Nature 383 (1996) 837
32. Virgilio F.D., Milani D., Leon A., Meldolesi J., and Pozzan T. J. Biol. Chem. 262 (1987) 9189
33. Habeeb A.G., Praveen Rao P.N., and Knaus E.E. J. Med. Chem. 44 (2001) 3039
34. Ishikawa J., Ohga K., Yoshino T., Takezawa R., Ichikawa A., Kubota H., and Yamada T. J. Immunol. 170 (2003) 4441
35. Elwood W., Lotvail J.O., Barnes P.J., and Chung K.F. Am. Rev. Respir. Dis. 145 (1992) 1289
36. CRAC channel have been recently reported to express in skeletal muscles and some regions of the brain, heart and kidney (Vig M. et al., Nat. Immunol. 2008, 9, 89). The synthesized compounds have not been evaluated for their in vitro effects on cardiomyocytes, however, some inhibitors including 6 exerted no effects on blood pressure and heart rate at doses of which exhibit anti-inflammatory activities (data not shown).